VANCOUVER, British Columbia, May 12, 2015 (GLOBE NEWSWIRE) -- M Pharmaceutical Inc. (CSE:MQ) (the "Company"), a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes, announced today that it has achieved an important milestone in the development of the e-Mosquito, a wearable blood glucose monitoring system designed for diabetics.
A human testing pilot demonstrated that a single-cell e-Mosquito prototype -- utilizing the innovative technology of shape memory alloys (SMA) -- was able to penetrate the skin, reach a subcutaneous capillary and extract a miniscule whole blood sample for further in-situ glucose analysis.
"This is an exciting milestone in the development of the e-Mosquito technology and our electronically-controlled microsystem for minimally-invasive, periodic sampling of whole blood for the purpose of autonomous glucose monitoring in diabetics," said Dr. Martin Mintchev, President & Chief Executive Officer of the Company.
"Simply put, we have demonstrated the practical feasibility of the e-Mosquito actuator, for which the Company has a pending patent," explained Dr. Mintchev, who has based his long-standing research and biomedical technology development at the University of Calgary in Alberta.
The Company views the milestone as a big step forward in the development of a six-cell, autonomous e-Mosquito prototype and an integrated electronic glucose analysis system. It will now allow the Company to perform statistically sound, comprehensive, and comparative human testing in its quest to operationalize the e-Mosquito technology.
"We're gratified by the results and look forward to taking the e-Mosquito technology to the level of pre-registration clinical trials," said Dr. Mintchev.
The Company already has acquired or agreed to acquire two other biomedical technologies at the stage of pre-registration clinical trials, both of which are also designed to improve the lives of people dealing with obesity or diabetes: implantable gastric neurostimulators and ingestible pseudobezoars.
About M Pharmaceutical Inc.
M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of the eMosquito, the pseudobezoar and the neurostimulator technologies will require successful coordination and execution of a wide variety of technology disciplines.
FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito and the temporary pseudobezoars. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to complete the commercialization of the eMosquito and the temporary pseudobezoars.
Investor Relations Phone: 604.428.0511 www.m-pharma.ca
